How to Value an Injection Molding Business in 2026

Injection molding is one of the few bright spots left in American custom manufacturing. The multiples hold up, private equity is active, and the deal flow hasn't cratered the way it has in tool and die. But within the category, the spread between a great shop and a mediocre one is enormous — I've sold $2M EBITDA molders for 6.5x and I've sold $2M EBITDA molders for 3.2x. Same category, same revenue, double the enterprise value.

The difference comes down to end-market, automation, and whether the shop owns its own tooling or runs customer-owned molds. Here's what actually drives injection molding valuations in 2026.

The Baseline: 3-6x EBITDA With a Wide Spread

Custom injection molders typically trade in a 3.0-6.0x adjusted EBITDA range. Commodity packaging molders anchor the bottom, food-grade and medical molders anchor the top, and automotive tier 2 and industrial OEM suppliers land in the middle at 3.5-4.5x.

A $10M revenue custom molder running 10-15 presses between 50 and 500 tons, serving industrial and consumer product customers, with $1.8M in adjusted EBITDA, will typically sell between $6.5M and $9M. A comparable shop running ISO 13485 medical work sells for $11M-$14M. The medical premium alone is worth $4-5M of enterprise value on the same financial profile.

Active PE platforms in this space include Wind Point Partners (Pexco), Mill Point Capital, and Nautic Partners. On the strategic side, Nypro (Jabil), Tessy Plastics, and Berry Global are the usual names at the table for larger assets. Below $2M EBITDA, the buyer pool shifts toward independent sponsors, family offices, and SBA-backed individual buyers.

Customer-Owned vs. Shop-Owned Tooling

This is the first question I ask when a molder calls me. Who owns the molds?

In most custom molding, the customer owns the tooling. They paid $40K-$200K for each mold, it sits on your floor, and you run it under a supply agreement. That's fine — it's the industry standard — but it has a real valuation implication. Customer-owned tooling means customers can move their tools to another molder with 30-60 days notice. Your "captive" revenue isn't actually captive.

Buyers heavily discount revenue from customer-owned tooling unless you have:

• Multi-year supply agreements with pricing protections and minimum volume commitments
• Tool ownership clauses requiring customer payment of "last shot" and tool transfer fees
• Deep qualification into the customer's product — PPAP approval for automotive, validation for medical
• Secondary operations (assembly, decorating, packaging) that make switching molders operationally expensive

Without these protections, a buyer looks at customer-owned tooling revenue and treats it like spot revenue — worth maybe 2-3x EBITDA contribution rather than 5-6x. If you're running captive molds under real supply agreements, you're worth significantly more. Make sure your data room shows those agreements prominently.

The Food-Grade and Medical Premium

ISO 13485 medical molding and food-grade (FDA 21 CFR, NSF) packaging are where the premium multiples live. A shop with legitimate medical device customers — real Class I and Class II approvals, not just "we run some medical parts" — trades at 5.5-7x EBITDA. Food-grade packaging molders serving brand-name CPG customers trade at 5-6x.

The reason is barriers to entry. Medical qualification takes 12-24 months and requires clean rooms, validated processes, and documented quality systems. Customers don't switch suppliers on a whim — moving a validated mold to a new supplier can take 6-12 months and cost $100K-$500K in revalidation. That stickiness translates directly into multiple expansion.

A clean room certified to ISO Class 8 (100,000) with documented operating procedures is essentially a moat. Buyers will pay up for it because they cannot replicate it inside an existing facility without major capital investment and a long qualification runway.

Automotive PPAP-level qualification has similar dynamics, but automotive multiples have compressed over the last five years because of EV disruption. Molders heavily exposed to ICE drivetrain components are now trading at discounts because buyers worry about the terminal value of those programs.

Press Tonnage Mix and Asset Utilization

Press fleet matters more than it does in CNC machining because mold utilization drives profitability and because tonnage mix determines what work you can and can't take. Buyers look at:

Press count and age. Modern all-electric presses (Engel, Sumitomo SHI Demag, Nissei) get valuation credit because they run faster, consume less energy, and require less maintenance. Shops still running 1990s-era hydraulic Van Dorns get dinged on forward capex assumptions.

Tonnage distribution. A shop with presses clustered around one tonnage range (say, 150-300 ton) has limited flexibility. A shop spanning 50 to 1,000+ tons can take more diverse work but also carries more capex. Buyers prefer focused fleets aligned to a specific end-market.

Utilization. A shop running 90%+ utilization on a 24/7 schedule looks great operationally but leaves no room for new customer wins — meaning the EBITDA growth story is capped without capex. A shop at 55-65% utilization has growth runway, and buyers credit that in DCF modeling.

Automation Is Worth a Full Turn

Labor is the constraint in custom molding. Every shop I visit is understaffed. Automation — robotic part removal, automated secondary operations, vision systems, auto-packing — is how profitable shops scale without doubling headcount.

Molders with robots on 70%+ of their presses and automated downstream operations consistently get 0.75-1.25 turns of premium on the EBITDA multiple. The reason is forward-looking: buyers know they can't hire their way to growth, and they'll pay for a shop that's already solved the labor problem.

The corollary is ugly. Molders running fully manual secondary operations, with high direct labor as a percentage of revenue, get discounted. Buyers will model wage inflation of 4-5% annually against your margin and adjust the multiple down accordingly. This is one of the single biggest value drivers in the industry right now.

What Kills Injection Molding Deals

The deals I've seen blow up in diligence almost always come down to the same issues:

Unreported scrap and quality costs. Molders often hide scrap in material variance or don't track it cleanly. Quality of earnings teams find it, and it comes out of your reported EBITDA. I've seen shops lose $300K of EBITDA to scrap normalization alone.

Resin pass-through mechanics. If your pricing doesn't have contractual resin escalators, a buyer will model margin volatility and discount accordingly. Shops with clean resin pass-throughs get credit for stable margins through cycles.

Single-customer dependencies.40%+ concentration is the breakpoint where buyers start requiring big earnouts. I've seen deals that would have been 5x EBITDA drop to 3.5x plus a 36-month earnout because of concentration.

Deferred press maintenance. A buyer's technical diligence team will inspect every press. Worn screws, leaking hydraulics, and outdated controls translate into a capex reserve on the closing balance sheet that comes out of seller proceeds.

The Bottom Line

Injection molding rewards the owners who've invested — in automation, in clean rooms, in qualifications, in customer diversification. It punishes the ones who've milked their presses without reinvesting. The spread between a 3x and a 6x multiple on a $2M EBITDA shop is $6 million of enterprise value, and that gap reflects decisions owners made five to ten years before they brought the business to market. If you're 24-36 months out, the biggest returns on your time are qualifying into food or medical end-markets, automating your secondary operations, and tightening up the quality of your reported earnings.